Last reviewed · How we verify

Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer

NCT00003533 PHASE2 TERMINATED

Current therapies for Metastatic Pancreatic Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Metastatic Pancreatic Cancer. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Metastatic Pancreatic Cancer.

Details

Lead sponsorBurzynski Research Institute
PhasePHASE2
StatusTERMINATED
Enrolment12
Start dateTue Feb 27 1996 00:00:00 GMT+0000 (Coordinated Universal Time)
CompletionFri Dec 31 1999 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Interventions

Countries

United States